

REMARKS

Reconsideration and withdrawal of the rejections of the application are respectfully requested in view of the remarks herein. The Examiner is thanked for withdrawing the previous art rejections based on Krieg.

I. STATUS OF THE CLAIMS AND FORMAL MATTERS

Claims 1, 3-4, 6-17, 20-26, 28-32 and 35-40 and 42 are now pending. Claims 16, 25, 32 and 43 have been cancelled herein, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

No new matter is added.

It is submitted that these claims are and were in full compliance with the requirements of 35 U.S.C §112. In addition, the amendment and remarks herein are not made for the purpose of patentability within the meaning of 35 U.S.C. §§101, 102, 103 or 112; but rather the amendments and remarks herein are made simply for clarification and to round out the scope of protection to which Applicants are entitled. Support for the amended claims is found throughout the specification.

It is noted that Applicants continue to disagree with the priority date assigned this application.

II. THE OBJECTIONS TO THE CLAIMS ARE OVERCOME

Claim 16 was objected to as providing an abbreviation without first providing the full name of the protein. Claim 43 was objected to as missing a verb. Applicants respectfully submit that the objections to claims 16 and 43 have been overcome by the amendments herein, such that the objections are now moot. Accordingly, reconsideration and withdrawal of the objections to claims 16 and 43 is respectfully requested.

Claim 43 was also objected to as being a substantial duplicate of claim 42. Applicants will revisit this objection at such time when either claim 42 or 43 has been found allowable.

III. THE REJECTIONS UNDER 35 U.S.C. §112 ARE OVERCOME

Claims 25 and 30-32 were rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter of the invention.

Specifically, the Office Action stated that there was no antecedent basis for the recitation of "bacterium" in claim 25. Further, claim 32 was considered indefinite for being dependent on a cancelled claim.

Applicants respectfully submit that the amendments herein have rendered these rejections moot. Accordingly, reconsideration and withdrawal of the rejection of the claims under 35 U.S.C. §112, second paragraph, is respectfully requested.

III. THE ART REJECTIONS ARE OVERCOME

Claims 1, 9-15, 21-23, 26, 28-29, 38 and 42-43 were rejected under 35 U.S.C. §102(e) as allegedly being anticipated by Roop et al. (US 6,143,727). Claims 1, 9-15, 21-23, 26, 28-29, 38 and 42-43 were rejected under 35 U.S.C. §102(e) as allegedly being anticipated by Carson et al. (US 5,679,647). Claims 1, 4, 16-17, 24-25, 30-31, 35-37 and 40 were rejected under 35 U.S.C. §103(a) as allegedly being unpatentable over either Powell et al. (US 5,877,159) or WO 01/89535 in view of Roop. Claims 1, 29 and 39 were rejected under 35 U.S.C. §103(a) as allegedly unpatentable over either Carson et al. or Roop et al., in view of either Alexander or Li.

Applicants respectfully remind the Examiner that a two-prong inquiry must be satisfied in order for a Section 102 rejection to stand. First, the prior art reference must contain all of the elements of the claimed invention, *see Lewmar Marine Inc. v. Barient Inc.*, 3 U.S.P.Q.2d 1766 (Fed. Cir. 1987), and, the single prior art reference must contain an enabling disclosure, *see Chester v. Miller*, 15 U.S.P.Q.2d 1333, 1336 (Fed. Cir. 1990).

Furthermore, the Examiner respectfully reminded that for a Section 103 rejection to be proper, there must be some prior art teaching which would have provided the necessary incentive or motivation for modifying the reference teachings to arrive at the claimed invention. *In re Laskowski*, 12 U.S.P.Q. 2d 1397, 1399 (Fed. Cir. 1989); *In re Obukowitz*, 27 U.S.P.Q. 2d 1063 (BOPAI 1993). Further, the Examiner is respectfully reminded that "obvious to try" is not the standard under 35 U.S.C. §103. *In re Fine*, 5 U.S.P.Q. 2d 1596, 1599 (Fed. Cir. 1988). And, as stated by the Court in *In re Fritch*, 23 U.S.P.Q. 2d 1780, 1783-1784 (Fed. Cir. 1992): "The mere

fact that the prior art may be modified in the manner suggested by the Examiner does not make the modification obvious unless the prior art suggests the desirability of the modification." Also, the Examiner is additionally respectfully reminded that for the Section 103 rejection to be proper, **both the suggestion of the claimed invention and the expectation of success must be founded in the prior art, and not Applicants' disclosure.** *In re Dow*, 5 U.S.P.Q.2d 1529, 1531 (Fed. Cir. 1988).

The Examiner is also respectfully reminded that MPEP 2143.01 mandates that for a Section 103 rejection, there must be some suggestion or motivation to modify reference teachings, and, that MPEP 2143.02 further mandates that for a section 103 rejection, there must be a reasonable expectation of success.

Both Roop and Carson relate to the administration of plasmid vectors, not "bacterial vectors" as is required by the pending claims. The Office Action attempts to equate plasmid vectors with "bacterial vectors" because "a plasmid vector contains bacterial sequences and it is propagated and selected in bacteria using a selective marker." Office Action at 5 and 7. Applicants respectfully submit that such a reading fails to take into consideration the meaning of the term "bacterial vector" as described in the specification and as known in the art.

Indeed, when interpreting the scope of the pending claims, including the term "bacterial vector", the claims must be read in light of the specification and the art as a whole.

One of skill in the art is certainly aware that plasmid vectors are small circular molecules of double stranded DNA derived from natural plasmids that occur in bacterial cells. That is, a plasmid vector is not a bacterial vector, rather, plasmid vectors can exist in bacteria. The term "bacterial vector" as used herein does not refer to a vector taken from within a bacteria, i.e., it does not refer to plasmid vectors that are only a portion of what makes up a bacteria. Rather, the term "bacterial vector" is used to indicate a vector comprising a bacteria, which bacteria can contain and express a nucleic acid molecule encoding a gene product of interest. Indeed, a plasmid vector cannot be considered a bacteria vector as it does not encompass the bacteria itself.

Accordingly, as neither Carson nor Roop either teach or suggest the use of bacterial vectors as the term is recognized and used in the art, the rejections based on these references cannot stand. As each and every art rejection provided in the Office Action rely on Roop and/or Carson, Applicants respectfully submit that the rejections must therefore be withdrawn.

Consequently, reconsideration and withdrawal of the rejections under 35 U.S.C. §§ 102(e) and 103(a) are respectfully requested.

IV. THE DOUBLE PANTENTING REJECTIONS ARE OVERCOME

Claim 41 was objected to under 37 C.F.R. § 1.75 as allegedly being a substantial duplicate of claim 1. The objection is respectfully traversed. Claim 41 has been cancelled herein without prejudice, rendering the objection moot.

Claims 1, 4, 6, 9-17, 20-26, 28-32, 35-40 and 42-43 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting as allegedly being unpatentable over claims 1-42 of copending Application Serial No. 10/346,021. And, claims 1, 11-13, 25, 28-29 and 38-39 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting as allegedly being unpatentable over claims 1, 6-8, 20, 23-24 and 33-34 of copending Application Serial No. 10/116,963. The rejections are respectfully traversed.

Applicants verily believe that the present application is in condition for allowance as a result of the amendments and remarks herein. Accordingly, as neither USSN 10/116,963 nor 10/346,021 have been found allowable, it is respectfully requested that the provisional double-patenting rejections be withdrawn in favor of a double patenting rejection in each of USSNs 10/116,963 and 10/346,021 over the present application.

REQUEST FOR INTERVIEW

If any issue remains as an impediment to allowance, prior to issuance of any paper other than a Notice of Allowance, an interview, is respectfully requested, with the Examiner and his supervisor, and, the Examiner is respectfully requested to contact the undersigned to arrange a mutually convenient time and manner for such an interview.

CONCLUSION

In view of the amendments, and remarks herein, the application is in condition for allowance. Reconsideration and withdrawal of the rejections of the application, and prompt issuance of a Notice of Allowance, is respectfully requested.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By: Thomas J. Kowalski by Angela M. Collison
Thomas J. Kowalski
Reg. No. 32,147
Angela M. Collison
Reg. No. 51,107
(212) 588-0800